SALL1 Protein

SALL1 Protein (Sal-like protein 1)

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8d8c8; text-align:center; font-size:1.1em;">Sal-like protein 1 (SALL1)</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Sal-like protein 1</td></tr>
<tr><td><strong>Gene</strong></td><td><a href="/genes/sall1">SALL1</a></td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/Q9BX63" target="_blank">Q9BX63</a></td></tr>
<tr><td><strong>PDB Structures</strong></td><td>No PDB structure available</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>144,000 Da</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Nucleus</td></tr>
<tr><td><strong>Protein Family</strong></td><td>SALL family, C2H2 zinc finger family</td></tr>
<tr><td><strong>Protein Length</strong></td><td>1,322 amino acids</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">9 edges</a></td>
</tr>
</table>
</div>

Overview

SALL1 Protein (Sal-like protein 1)

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8d8c8; text-align:center; font-size:1.1em;">Sal-like protein 1 (SALL1)</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Sal-like protein 1</td></tr>
<tr><td><strong>Gene</strong></td><td><a href="/genes/sall1">SALL1</a></td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/Q9BX63" target="_blank">Q9BX63</a></td></tr>
<tr><td><strong>PDB Structures</strong></td><td>No PDB structure available</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>144,000 Da</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Nucleus</td></tr>
<tr><td><strong>Protein Family</strong></td><td>SALL family, C2H2 zinc finger family</td></tr>
<tr><td><strong>Protein Length</strong></td><td>1,322 amino acids</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">9 edges</a></td>
</tr>
</table>
</div>

Overview

SALL1 (Sal-like protein 1) is a member of the SALL family of C2H2 zinc-finger transcription factors that plays a critical role in the development and maintenance of microglia, the resident immune cells of the central nervous system. First characterized for its role in organ development, SALL1 has emerged as a key molecular marker of homeostatic microglia and a regulator of the disease-associated microglia (DAM) phenotype in neurodegenerative conditions including Alzheimer's disease (AD) and Parkinson's disease (PD)[@tchieu2019].

The protein is predominantly expressed in microglia within the brain, where it serves as a master regulator of microglial identity, controlling the expression of genes essential for microglial survival, function, and transformation into disease-associated states. Loss of SALL1 expression is considered a hallmark of microglial dysregulation in neurodegenerative disease[@zhao2022].

Molecular Structure

SALL1 is a large transcription factor comprising 1,322 amino acids with the following structural features:

Domain Architecture

• C2H2 Zinc Finger Domains: SALL1 contains multiple C2H2 zinc finger motifs (approximately 10 zinc fingers) that mediate DNA binding to specific promoter and enhancer regions[@schneeberger2019]. These zinc fingers recognize the consensus sequence (GGAA/T) and enable targeting of gene regulatory elements.
• Transcription Repressor Domain: The N-terminal region contains a transcriptional repressor domain that recruits chromatin-modifying complexes, including histone deacetylases (HDACs) and the Nucleosome Remodeling and Deacetylase (NuRD) complex.
• Dimerization Domain: SALL1 can form homodimers through its C-terminal region, enabling cooperative DNA binding and transcriptional regulation.

Post-Translational Modifications

• Phosphorylation: SALL1 activity is modulated by phosphorylation events that affect its DNA-binding affinity and protein-protein interactions.
• Sumoylation: Sumoylation of SALL1 influences its transcriptional repressor function and subnuclear localization.

Normal Physiological Function

Microglial Development

During embryonic development, SALL1 is expressed in yolk sac-derived microglial precursors and is essential for the specification of the microglial lineage[@butovsky2014]. It controls the transcriptional program that distinguishes microglia from other tissue macrophages, including expression of genes involved in:

• Immune surveillance
• Synaptic pruning
• Brain homeostasis maintenance

Adult Brain Function

In the adult brain, SALL1+ microglia represent the predominant population and are characterized by[@sink2020]:

• High expression of microglial signature genes (CX3CR1, P2RY12, TMEM119)
• Enhanced phagocytic capacity
• Anti-inflammatory phenotype
• Metabolic fitness for brain homeostasis

Role in Neurodegenerative Diseases

Alzheimer's Disease

SALL1 plays a complex and context-dependent role in Alzheimer's disease pathogenesis:

Disease-Associated Microglia Transition: During AD progression, microglia undergo a transformation from a homeostatic (SALL1+) state to a disease-associated (SALL1-low/null) state. This transition is characterized by[@krasemann2017]:

• Downregulation of SALL1 and other homeostatic genes
• Upregulation of TREM2, APOE, and pro-inflammatory genes
• Acquisition of a phagocytic but potentially harmful phenotype

Therapeutic Implications: Targeting SALL1 modulation represents a novel therapeutic approach for AD. Strategies under investigation include[@fan2022]:

• SALL1 expression restoration using viral vectors
• Epigenetic therapies to reactivate SALL1 transcription
• Small molecules that stabilize SALL1 protein

Parkinson's Disease

In Parkinson's disease, SALL1+ microglia are similarly affected:

• SALL1 expression is reduced in substantia nigra microglia
• Loss of SALL1 correlates with increased neuroinflammation in PD models
• SALL1 deficiency exacerbates dopaminergic neuron loss through enhanced microglial activation

Other Neurodegenerative Conditions

SALL1 dysregulation has been implicated in:

• Amyotrophic Lateral Sclerosis (ALS): SALL1+ microglia show reduced coverage of motor neurons
• Multiple Sclerosis: SALL1 expression inversely correlates with lesion activity
• Frontotemporal Dementia: Microglial SALL1 loss associated with TDP-43 pathology

Signaling Pathways and Interactions

TREM2-APOE-SALL1 Axis

SALL1 interacts closely with the TREM2-APOE signaling pathway, a critical regulator of microglial function[@wang2023]:

ApoE/TREM2 signaling --> SALL1 expression --> Microglial phenotype
↓ ↓
Lipid metabolism Chromatin remodeling
↓ ↓
DAM phenotype Inflammatory gene repression

This axis governs the metabolic and functional transformation of microglia in neurodegenerative conditions.

TGF-beta Signaling

TGF-beta signaling is a key upstream regulator of SALL1 expression. Microglial SALL1 expression is induced by TGF-beta and maintained through the TGF-beta receptor signaling cascade[@butovsky2014]. Disruption of TGF-beta signaling leads to SALL1 downregulation and microglial dysfunction.

Chromatin Remodeling Complexes

SALL1 recruits multiple chromatin remodeling complexes:

• NuRD Complex: Mediates histone deacetylation and nucleosome remodeling at target genes
• Polycomb Repressive Complex 2 (PRC2): Deposits H3K27me3 marks for gene silencing
• SWI/SNF Complex: Facilitates ATP-dependent chromatin remodeling

Therapeutic Targeting

Current Strategies

Challenges

• Blood-brain barrier delivery to microglia
• Achieving appropriate SALL1 expression levels (both insufficient and excessive can be problematic)
• Cell-type specific targeting to avoid off-target effects

Preclinical Progress

Recent studies have shown promise:

• AAV-mediated SALL1 delivery reduces neuroinflammation in AD mouse models[@holland2023]
• SALL1 overexpression improves synaptic function and cognitive performance
• Combined SALL1 and TREM2 modulation shows synergistic benefits[@wang2023]

Expression Patterns

Brain Region Distribution

SALL1+ microglia are distributed throughout the brain with highest density in:

• Hippocampus (particularly CA1 and dentate gyrus)
• Cerebral cortex (layer 2/3)
• Cerebellum (Purkinje cell layer)
• Substantia nigra (pars reticulata)

Age-Related Changes

SALL1 expression in microglia declines with age[@sink2020]:

• Young brain: >95% of microglia are SALL1+
• Aged brain: SALL1+ microglia reduced to ~70%
• This age-related decline may contribute to increased neuroinflammation and cognitive decline

Disease-Associated Changes

In neurodegenerative diseases, SALL1 expression shows:

• Early stage AD: Moderate reduction (SALL1+ ~60-70%)
• Advanced AD: Severe reduction (SALL1+ <30%)
• Similar patterns observed in PD, ALS, and FTD

Key Research Findings

| Year | Finding | Reference |
|------|---------|-----------|
| 2019 | SALL1 defines microglial activation state | [@tchieu2019] |
| 2022 | SALL1 controls inflammatory response in AD | [@zhao2022] |
| 2022 | Spatial profiling of SALL1+ microglia in AD | [@masuda2022] |
| 2023 | Restoring SALL1 improves cognitive function | [@holland2023] |
| 2023 | SALL1-TREM2 crosstalk in microglial activation | [@wang2023] |
| 2024 | Epigenetic remodeling of SALL1 in DAM | [@yoshikawa2024] |

See Also

• [SALL1 Gene](/genes/sall1)
• [Microglial Transcription Factors](/mechanisms/microglial-transcription-factors)
• [Disease-Associated Microglia (DAM)](/mechanisms/disease-associated-microglia)
• [TREM2 Signaling Pathway](/mechanisms/trem2-signaling)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease))